GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6455 Idazoxan hydrochlorideSummary: α2-adrenoceptor antagonist -
B5444 SB 243213 dihydrochlorideSummary: Selective 5-HT2C inverse agonist -
B6454 Efaroxan hydrochlorideSummary: α2 adrenoceptor antagonist and imidazoline I1 receptor ligand -
B5348 SB 242084Summary: 5-HT2C receptor antagonist -
B6397 2-MPMDQSummary: α1-adrenoceptor antagonist,potent and selective -
B5344 DOB hydrochlorideSummary: Selective 5-HT2 receptor agonist -
B6384 SpiroxatrineSummary: 5-HT1A antagonist and α2C adrenergic receptor antagonist -
B5334 SB 258719 hydrochlorideSummary: Selective 5-HT7 receptor antagonist -
B6382 2-PMDQSummary: α1-adrenoceptor antagonist -
B5321 DOI hydrochlorideTarget: 5-HT2 ReceptorsSummary: A brain-permeable 5-HT2A/5-HT2C receptor agonist
